Health and Healthcare

Short Sellers Grow More Selective on Major Pharma Stocks

Chris Lange

Published: April 25, 2018 8:35 am

Last Updated: January 12, 2020 12:31 am

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.

The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It has yet to be seen how much headway they can actually make with these reforms.

Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.

The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.

Short interest in Pfizer Inc. (NYSE: PFE) decreased to 81.03 million shares from the previous 98.32 million. The stock was last seen trading at $37.06, within a 52-week range of $31.67 to $39.43.

The number of Merck & Co. Inc. (NYSE: MRK) shares short decreased to 22.95 million from 23.67 million in the previous period. Its shares were trading at $60.09, in a 52-week range of $52.83 to $66.41.

Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest decreased to 55.84 million from the previous level of 59.40 million. Shares were trading at $17.56, in a 52-week range of $10.85 to $33.82.

Bristol-Myers Squibb Co. (NYSE: BMY) short interest increased to 14.32 million shares from the previous reading of 11.14 million. Shares were trading at $51.58, within a 52-week range of $50.66 to $70.05.

The number of shares short in AbbVie Inc. (NYSE: ABBV) increased to 15.66 million, compared to the previous 15.25 million. The stock was trading at $91.36, in a 52-week range of $64.61 to $125.86.

Eli Lilly and Co.’s (NYSE: LLY) short interest decreased to 9.66 million shares from the previous 10.53 million. The stock was trading at $80.09. The 52-week range is $73.69 to $89.09.